<DOC>
	<DOCNO>NCT00062764</DOCNO>
	<brief_summary>Nonalcoholic steatohepatitis ( NASH ) common liver disease resemble alcoholic hepatitis occur person drink little alcohol . The etiology NASH unclear , commonly associate diabetes , obesity , insulin resistance . Several pilot study , include study pioglitazone NIH Clinical Center ( 01-DK-0130 ) , show insulin-sensitizing thiazolidinediones lead decrease serum alanine aminotransferase ( ALT ) level improve liver histology . Once therapy stop , however , ALT level rapidly return pre-treatment value . Inaddition currently enrol patient NASH pilot study metformin therapy 48-weeks , however result 3 patient thus far encouraging . In current study , patient complete pilot study pioglitazone therapy 48 week offer re-treatment 3 year . We also propose treat patient satisfactory response metformin pioglitazone duration . After repeat medical metabolic evaluation liver biopsy , patient moderate-to-severe NASH ( activity score great equal 4 ) restart pioglitazone dose 15 mg daily . If 48 week , ALT level normal improve degree identify pilot study , dose increase 30 mg daily end 3 year , patient undergo repeat medical metabolic evaluation liver biopsy . The primary end point improvement liver histology . Secondary end point improvement insulin sensitivity , reduction visceral fat , liver volume , liver biochemistry . The aim study evaluate whether long-term pioglitazone therapy safely achieve maintain biochemical histological improvement NASH .</brief_summary>
	<brief_title>Treating Nonalcoholic Steatohepatitis With Pioglitazone</brief_title>
	<detailed_description>Nonalcoholic steatohepatitis ( NASH ) common liver disease resemble alcoholic hepatitis occur person drink little alcohol . The etiology NASH unclear , commonly associate diabetes , obesity , insulin resistance . Several pilot study , include study pioglitazone NIH Clinical Center ( 01-DK-0130 ) , show insulin-sensitizing thiazolidinediones lead decrease serum alanine aminotransferase ( ALT ) level improve liver histology . Once therapy stop , however , ALT level rapidly return pre-treatment value . Inaddition currently enrol patient NASH pilot study metformin therapy 48-weeks , however result 3 patient thus far encouraging . In current study , patient complete pilot study pioglitazone therapy 48 week offer re-treatment 3 year . We also propose treat patient satisfactory response metformin pioglitazone duration . After repeat medical metabolic evaluation liver biopsy , patient moderate-to-severe NASH ( activity score great equal 4 ) restart pioglitazone dose 15 mg daily . If 48 week , ALT level normal improve degree identify pilot study , dose increase 30 mg daily end 3 year , patient undergo repeat medical metabolic evaluation liver biopsy . The primary end point improvement liver histology . Secondary end point improvement insulin sensitivity , reduction visceral fat , liver volume , liver biochemistry . The aim study evaluate whether long-term pioglitazone therapy safely achieve maintain biochemical histological improvement NASH .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>INCLUSION CRITERIA : Completion 48week course pioglitazone protocol 01DK0130 completion 48weeks metformin protocol 03DK0233 . At least 48 week follow thiazolidinedione therapy completion protocol 01DK0130 . At least 24weeks follow metformin theray completion protocol 03DK0233 . Written informed consent . Patients participate protocol 01DK0130 also meet follow inclusion criterion : Demonstrated improvement liver histology and/or serum ALT level 48week course pioglitazone therapy protocol 01DK0130 . Elevations serum ALT level . Liver biopsy show NASH total NASH activity score least 4 ( total possible score 16 ) include score least 1 parenchyma inflammation , cellular injury steatosis liver biopsy take 48 week stop pioglitazone . Willingness receive pioglitazone 3 year . Patients participate protocol 03DK0233 also follow inclusion criterion : Demonstrated significant improvement liver histology and/or serum ALT level 48week course metformin treatment protocol 03DK0233 . Elevations serum ALT level . Liver biopsy show NASH total activity score least 4 ( total possible score 16 ) include score least 1 parenchymal inflammation , cellular injury steatosis liver biopsy take end 48week course metofrmin . EXCLUSION CRITERIA : Evidence another form liver disease ( largely exclude base upon enrollment previous study , 01DK0130 03DK0233 ) . Hepatitis B define presence hepatitis B surface antigen ( HBsAg ) . Hepatitis C define presence hepatitis C virus ( HCV ) RNA serum . Autoimmune hepatitis define antinuclear antibody ( ANA ) 1:160 great liver histology consistent autoimmune hepatitis previous response immunosuppressive therapy . Autoimmune cholestatic liver disorder define elevation alkaline phosphatase antimitochondrial antibody great 1:80 liver histology consistent primary biliary cirrhosis elevation alkaline phosphatase liver histology consistent sclerosing cholangitis . e. Wilson disease define ceruloplasmin limit normal liver histology consistent Wilson disease . Alpha1antitrypsin deficiency define alpha1antitrypsin level less normal liver histology consistent alpha1antitrypsin deficiency . Hemochromatosis define presence 3+ 4 iron liver biopsy stain homozygosity C282Y compound heterozygosity C282Y/H63D . Druginduced liver disease define basis typical exposure history . Bile duct obstruction show imaging study . History excess alcohol ingestion , average 30 gm/day ( 3 drink per day ) previous 10 year , history alcohol intake average great 10 gm/day ( 1 drink per day : 7 drink per week ) previous one year . Contraindications liver biopsy : platelet count less 75,000/mm ( 3 ) prothrombin time great 16 second . Decompensated liver disease , ChildPugh score great equal 7 point . History gastrointestinal bypass surgery ingestion drug know produce hepatic steatosis include corticosteroid , highdose estrogen , methotrexate , tetracycline amiodarone previous 6 month . Preexistent diabetes mellitus development diabetes mellitus study require use another drug addition pioglitazone glycaemic control . Diabetes define : fasting plasma glucose great equal 126 mg/dl two separate occasion , diabetic symptom random plasma glucose great equal 200 mg/dl . Use antidiabetic drug , include insulin , biguanides , sulfonylurea , thiazolidinediones time enrollment previous 48 week . Significant systemic major illness liver disease , include congestive heart failure , coronary artery disease , cerebrovascular disease , pulmonary disease , renal failure , organ transplantation , serious psychiatric disease , malignancy , opinion investigator would preclude treatment pioglitazone adequate follow . Positive test antiHIV . Active substance abuse , alcohol , inhale injection drug within previous one year . Pregnancy inability practice adequate contraception woman childbearing potential . Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . Any condition , , opinion investigator would impede competence compliance possibility , hind completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Insulin Resistance</keyword>
	<keyword>Obesity</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Peroxisome Proliferator-Advanced Receptor Gamma</keyword>
	<keyword>PPAR Gama</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Non-Alcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
</DOC>